Literature DB >> 11604388

The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.

P M Clare1, R A Poorman, L C Kelley, K D Watenpaugh, C A Bannow, K L Leach.   

Abstract

cdk2.cyclin E and cdk5.p25 are two members of the cyclin-dependent kinase family that are potential therapeutic targets for oncology and Alzheimer's disease, respectively. In this study we have investigated the mechanism for these enzymes. Kinases catalyze the transfer of phosphate from ATP to a protein acceptor, thus utilizing two substrates, ATP and the target protein. For a two-substrate reaction, possible kinetic mechanisms include: ping-pong, sequential random, or sequential ordered. To determine the kinetic mechanism of cdk2.GST-cyclin E and cdk5.GST-p25, kinase activity was measured in experiments in which concentrations of peptide and ATP substrates were varied in the presence of dead-end inhibitors. A peptide identical to the peptide substrate, but with a substitution of valine for the phosphoacceptor threonine, competed with substrate with a K(i) value of 0.6 mm. An aminopyrimidine, PNU 112455A, was identified in a screen for inhibitors of cdk2. Nonlinear least squares and Lineweaver-Burk analyses demonstrated that the inhibitor PNU 112455A was competitive with ATP with a K(i) value of 2 microm. In addition, a co-crystal of PNU 112455A with cdk2 showed that the inhibitor binds in the ATP binding pocket of the enzyme. Analysis of the inhibitor data demonstrated that both kinases use a sequential random mechanism, in which either ATP or peptide may bind first to the enzyme active site. For both kinases, the binding of the second substrate was shown to be anticooperative, in that the binding of the first substrate decreases the affinity of the second substrate. For cdk2.GST-cyclin E the kinetic parameters were determined to be K(m, ATP) = 3.6 +/- 1.0 microm, K(m, peptide) = 4.6 +/- 1.4 microm, and the anticooperativity factor, alpha = 130 +/- 44. For cdk5.GST-p25, the K(m, ATP) = 3.2 +/- 0.7 microm, K(m, peptide) = 1.6 +/- 0.3 microm, and alpha = 7.2 +/- 1.8.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604388     DOI: 10.1074/jbc.M102034200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Understanding bistability in complex enzyme-driven reaction networks.

Authors:  Gheorghe Craciun; Yangzhong Tang; Martin Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

2.  Crystal structure of human CDK4 in complex with a D-type cyclin.

Authors:  Philip J Day; Anne Cleasby; Ian J Tickle; Marc O'Reilly; Joe E Coyle; Finn P Holding; Rachel L McMenamin; Jeff Yon; Rajiv Chopra; Christoph Lengauer; Harren Jhoti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  The interaction graph structure of mass-action reaction networks.

Authors:  Mirela Domijan; Elisabeth Pécou
Journal:  J Math Biol       Date:  2011-08-21       Impact factor: 2.259

4.  Insights into the phosphoryl transfer mechanism of cyclin-dependent protein kinases from ab initio QM/MM free-energy studies.

Authors:  Gregory K Smith; Zhihong Ke; Hua Guo; Alvan C Hengge
Journal:  J Phys Chem B       Date:  2011-11-03       Impact factor: 2.991

5.  Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies.

Authors:  Archana Jayaraman; Kaiser Jamil
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 6.  Structural insights into the functional diversity of the CDK-cyclin family.

Authors:  Daniel J Wood; Jane A Endicott
Journal:  Open Biol       Date:  2018-09       Impact factor: 6.411

7.  Mathematical model of hypoxia and tumor signaling interplay reveals the importance of hypoxia and cell-to-cell variability in tumor growth inhibition.

Authors:  Emile P Chen; Roy S Song; Xueer Chen
Journal:  BMC Bioinformatics       Date:  2019-10-21       Impact factor: 3.169

8.  The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.

Authors:  Sonja Baumli; Alison J Hole; Lan-Zhen Wang; Martin E M Noble; Jane A Endicott
Journal:  Structure       Date:  2012-09-06       Impact factor: 5.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.